How to access Cuvitru for primary immunodeficiency from Dubai: 2026 emirate pathway via Mediclinic City and American Hospital | Reserve Meds
*Clinically reviewed by Mohammad Ali, MD (US-trained physician, Chief AI Officer, Reserve Meds). Last reviewed 2026-05-20.
Dubai manages PI patients through allergy-immunology services at Mediclinic City Hospital, American Hospital Dubai, King's College Hospital Dubai, and at Al Jalila Children's Specialty Hospital for paediatric. The 2026 question is whether to convert to weekly self-administered SC Cuvitru.
Why Cuvitru, why now
Cuvitru (immune globulin subcutaneous, human - klhw) is a 20 percent subcutaneous immune globulin (SCIG) preparation manufactured by Takeda. The US FDA approved Cuvitru in September 2016 for the treatment of primary humoral immunodeficiency (PI) in adults and paediatric patients aged 2 years and older. Conditions covered include congenital agammaglobulinemia, common variable immunodeficiency (CVID), X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiency. The 20 percent concentration enables smaller infusion volumes than 10 percent SCIG products, supporting weekly home self-administration.
The 2026 question for a Dubai PI patient already on IVIG (Gammagard, Octagam, Privigen, or similar monthly products) is whether to convert to Cuvitru for steadier IgG troughs, reduced wear-off symptoms in the days before each infusion, less dependence on infusion-chair scheduling, or to avoid poor peripheral venous access. Cuvitru is also useful for frequent travellers who cannot reliably attend hospital appointments. Reserve Meds does not promote one IgG product over another. Alternatives include Hyqvia (SC with hyaluronidase, monthly), Hizentra (20 percent SC weekly), Octagam, Gammagard, Privigen, and others.
What Cuvitru is, in plain language
Cuvitru is a clear-to-slightly-opalescent 20 percent immune globulin liquid prepared from screened US plasma donors, manufactured with multiple viral inactivation and removal steps. It is injected under the skin at the abdomen or thigh using a small subcutaneous needle and a portable infusion pump. After clinic-supervised training (typically two to three sessions), the patient or caregiver self-administers at home, usually once weekly. Each infusion takes 60 to 90 minutes depending on dose and number of sites used. Steady-state IgG levels are achieved after several cycles, typically by week 8 to 12, with flatter and higher troughs than the IVIG sawtooth pattern.
Access pathway in Dubai
Dubai operates a two-tier regulatory framework. The Emirates Drug Establishment (EDE), formed in 2024 by consolidating the federal medicine regulatory mandate previously held by the Ministry of Health and Prevention (MOHAP), oversees federal-level medicine registration, import licensing, and pharmacovigilance. The Dubai Health Authority (DHA) governs healthcare facility licensing and clinical practice within the emirate. Cuvitru is not currently EDE-registered. Access therefore runs through an EDE-approved named-patient personal-import authorisation, with DHA acknowledgment, filed by the treating allergist-immunologist at Mediclinic City Hospital, American Hospital Dubai, King's College Hospital Dubai, or Al Jalila Children's Specialty Hospital (paediatric).
The treating physician submits a named-patient import application detailing the PI diagnosis, the rationale for SCIG conversion, prior IVIG experience, and the requested dose and shipment quantity. EDE reviews and issues an import authorisation per shipment. Reserve Meds sources Cuvitru from a US DSCSA-compliant specialty wholesaler, prepares the manufacturer pedigree and chain-of-custody documentation, and ships under validated cold chain to Dubai International Airport for clearance and hand-off to the hospital pharmacy.
Eligibility at a Dubai allergy-immunology clinic
Cuvitru eligibility requires a confirmed PI diagnosis with documented IgG deficiency, often with subclass deficiency, impaired specific antibody response (vaccine-challenge testing using pneumococcal polysaccharide or tetanus antigens), or genetic confirmation of a defined PI syndrome. The treating immunologist documents baseline IgG, IgA, IgM, specific antibody responses, infection history (sinopulmonary infections, otitis media, severe or recurrent infections), and confirms self-administration capability for the patient or caregiver. An IgG trough goal is established, typically 7 to 12 g/L depending on the syndrome and infection burden.
Documentation required
The patient and physician should be prepared to provide: a current Emirates ID or passport; the diagnostic immunology workup including immunoglobulin panels, vaccine-challenge responses, and any genetic confirmation; documentation of infection history; prior IVIG infusion records and any wear-off or tolerability issues; the treating immunologist's prescription on hospital letterhead; a clinical justification letter detailing the SCIG rationale; the EDE named-patient import application; the DHA acknowledgment; and evidence of payment capacity or insurance pre-authorisation. Reserve Meds prepares the US-side export documentation, manufacturer pedigree, and the customs packet.
Costs and funding considerations
The annual cost band for Cuvitru in Dubai is USD 75,000 to 110,000 per patient (AED 275,000 to 405,000), weight-and-dose dependent. Typical maintenance dosing is 100 to 200 mg/kg per week. DHA Saada coverage for Emirati nationals in Dubai may apply under the rare-disease provision on a case-by-case basis with the treating physician's documentation. Daman Enhanced, NEXtCARE, AXA, Allianz, Bupa Arabia, and Oman Insurance Dubai-licensed plans generally have pre-authorisation pathways for IVIG and SCIG when PI is confirmed. Reserve Meds will help structure the insurer or DHA Saada submission with the treating physician.
Typical timeline
Weeks 0 to 2: clinical eligibility review, EDE filing, prescription preparation, training arrangement. Weeks 2 to 4: shipment arrival at Dubai International Airport, clinic-supervised SC training (two to three sessions), home-environment setup. Weeks 4 to 16: weekly SC infusions at home with patient logs; IgG trough check at week 12. Months 6 and 12: full reassessment, infection-event log review, IgG and infection-frequency comparison versus the prior IVIG era, dose adjustment as needed.
When Cuvitru is the wrong drug
Patients with good venous access and no appetite for self-injection are usually better served by continuing IVIG. Patients unable to reliably self-administer (cognitive impairment, no caregiver) are safer on IVIG with hospital-supervised infusion. Patients who cannot maintain a weekly schedule may prefer Hyqvia (monthly SC with hyaluronidase). IgA-deficient patients with anti-IgA antibodies require additional caution and discussion of low-IgA product selection with the treating immunologist. Reserve Meds does not promote one IgG product over another.
Frequently asked questions
- Is the pathway legal in Dubai? Yes. It operates under EDE named-patient personal-import authorisation with DHA acknowledgment under federal UAE medicines law and DHA regulations.
- Will DHA Saada or my insurance cover Cuvitru? Emirati nationals may secure DHA Saada rare-disease support case-by-case; private insurance pre-authorisation is generally available where PI is confirmed.
- How is Cuvitru shipped? Validated cold chain (2 to 8 degrees Celsius) with temperature-monitored containers from a US DSCSA-compliant specialty wholesaler to Dubai International Airport.
- Can my child use Cuvitru? Cuvitru is FDA-approved for paediatric patients aged 2 and older; paediatric cases are typically managed at Al Jalila Children's Specialty Hospital in Dubai.
- What if Cuvitru is in short supply at the US level? Reserve Meds will inform you upfront and decline rather than promise a timeline we cannot deliver. We do not source from unverified channels.
Closing
Reserve Meds runs the Cuvitru supply file from the Mediclinic City, American Hospital Dubai, King's College, or Al Jalila Children's allergy-immunology referral through EDE named-patient authorisation and delivered cold-chain supply. Clinical decisions remain with your treating allergist-immunologist. To open a case, start your file in the patient portal or message us on WhatsApp; we will return a delivered quote within 24 hours.
Composite case examples; no individual patient is depicted. This content is for